Gefitinib's anti-lung cancer effects attribute to its binding to the adenosine triphosphate binding site in the tyrosine kinase domain of EGFR, thereby inhibiting EGFR kinase activity [3], [5], [34], [35]. The gene discussed is EGFR; the disease is lung carcinoma.